Oxford Immunotec Global (NASDAQ:OXFD) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Thursday. The brokerage currently has a $20.00 price objective on the stock. Zacks Investment Research‘s price target indicates a potential upside of 11.48% from the company’s current price.

According to Zacks, “Oxford Immunotec Global PLC is a medical diagnostics company. It develops new tests for various diseases based on its, patented T cell measurement technology. The company’s first product is the T-SPOT(R). Oxford Immunotec Global PLC is headquartered in Abingdon, the United Kingdom. “

Other research analysts have also issued reports about the company. ValuEngine lowered Oxford Immunotec Global from a “strong-buy” rating to a “buy” rating in a report on Saturday, December 1st. BidaskClub upgraded Oxford Immunotec Global from a “sell” rating to a “hold” rating in a report on Thursday, January 10th. Finally, Piper Jaffray Companies initiated coverage on Oxford Immunotec Global in a report on Friday, March 8th. They issued an “overweight” rating for the company. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $19.50.

OXFD opened at $17.94 on Thursday. The firm has a market cap of $474.77 million, a PE ratio of 35.18 and a beta of 0.36. Oxford Immunotec Global has a 52 week low of $11.66 and a 52 week high of $19.19.

Oxford Immunotec Global (NASDAQ:OXFD) last released its earnings results on Monday, March 11th. The company reported $1.25 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.19) by $1.44. The firm had revenue of $15.37 million during the quarter, compared to analyst estimates of $18.61 million. Oxford Immunotec Global had a return on equity of 14.26% and a net margin of 147.71%. As a group, equities research analysts predict that Oxford Immunotec Global will post -0.47 EPS for the current year.

In other Oxford Immunotec Global news, SVP Elizabeth M. Keiley sold 4,100 shares of the firm’s stock in a transaction on Monday, March 4th. The stock was sold at an average price of $17.00, for a total value of $69,700.00. Following the sale, the senior vice president now directly owns 26,928 shares in the company, valued at $457,776. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Peter Wrighton-Smith sold 10,000 shares of the firm’s stock in a transaction on Tuesday, February 19th. The shares were sold at an average price of $16.99, for a total value of $169,900.00. Following the completion of the sale, the chief executive officer now owns 413,469 shares in the company, valued at $7,024,838.31. The disclosure for this sale can be found here. Over the last quarter, insiders sold 27,100 shares of company stock valued at $431,450. 6.61% of the stock is currently owned by company insiders.

A number of institutional investors have recently bought and sold shares of the business. Vanguard Group Inc raised its stake in Oxford Immunotec Global by 2.0% in the third quarter. Vanguard Group Inc now owns 95,647 shares of the company’s stock valued at $1,552,000 after buying an additional 1,839 shares in the last quarter. Northern Trust Corp raised its stake in Oxford Immunotec Global by 0.7% in the fourth quarter. Northern Trust Corp now owns 290,723 shares of the company’s stock valued at $3,715,000 after buying an additional 2,113 shares in the last quarter. Essex Investment Management Co. LLC raised its stake in Oxford Immunotec Global by 2.0% in the fourth quarter. Essex Investment Management Co. LLC now owns 174,499 shares of the company’s stock valued at $2,230,000 after buying an additional 3,482 shares in the last quarter. New York State Common Retirement Fund raised its stake in Oxford Immunotec Global by 4.7% in the fourth quarter. New York State Common Retirement Fund now owns 77,631 shares of the company’s stock valued at $992,000 after buying an additional 3,500 shares in the last quarter. Finally, Wells Fargo & Company MN raised its stake in Oxford Immunotec Global by 11.2% in the third quarter. Wells Fargo & Company MN now owns 45,820 shares of the company’s stock valued at $744,000 after buying an additional 4,605 shares in the last quarter. Institutional investors own 89.92% of the company’s stock.

About Oxford Immunotec Global

Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for underserved immune-regulated conditions. Its development activities principally focus on the areas of infectious diseases, transplantation, autoimmune and inflammatory disease, and immune-oncology.

Recommended Story: How Does the Quiet Period Work?

Get a free copy of the Zacks research report on Oxford Immunotec Global (OXFD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.